(Reuters) – Stryker Corp forecast 2024 profit above Wall Street estimates on Tuesday, banking on a post-pandemic pick-up in volume for certain surgical procedures at hospitals to drive sales for its medical and surgical devices. Shares of the med-tech firm rose 3.2% to about $327 after the bell. Demand for medical devices has recently seen a surge as older adults in the United States are returning to hospitals for procedures such as joint replacements that were put off during the pandemic. The joint-implant maker sees its 2024 per share profit in the $11.70-$12.00 range, above analysts’ estima…